Home » Stocks » XERS

Xeris Pharmaceuticals, Inc. (XERS)

Stock Price: $3.19 USD -0.14 (-4.20%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $3.20 +0.01 (0.31%) May 13, 4:39 PM
Market Cap 220.89M
Revenue (ttm) 20.44M
Net Income (ttm) -91.14M
Shares Out 42.64M
EPS (ttm) -2.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $3.19
Previous Close $3.33
Change ($) -0.14
Change (%) -4.20%
Day's Open 3.66
Day's Range 3.05 - 3.68
Day's Volume 4,111,679
52-Week Range 2.45 - 7.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 3.23% and 6.42%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 hours ago - Zacks Investment Research

Shares of Xeris Pharmaceuticals (NASDAQ:XERS) rose 1.8% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 66.29% year over year to ($0.30), whic...

9 hours ago - Benzinga

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use i...

10 hours ago - Business Wire

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable dr...

3 days ago - Business Wire

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use i...

1 week ago - Business Wire

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use i...

1 week ago - Business Wire

Xeris Pharmaceuticals (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

CHICAGO & DUBLIN--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready...

2 weeks ago - Business Wire

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable an...

1 month ago - Business Wire

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Xeris Pharmaceuticals, Inc. ("Xeris" or the "Company") (NASDAQ: XERS). Such invest...

1 month ago - Newsfile Corp

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use i...

2 months ago - Business Wire

NEW YORK, March 10, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Xeris Pharmaceuticals, Inc. ("Xeris" or the "Company") (NASDAQ: XERS).  Such investors are advise...

2 months ago - PRNewsWire

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of -5.13% and -22.83%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CHICAGO--(BUSINESS WIRE)-- #T1D--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-t...

2 months ago - Business Wire

Xeris Pharmaceuticals (NASDAQ:XERS) unveils its next round of earnings this Tuesday, March 09. Get prepared with Benzinga's ultimate preview for Xeris Pharmaceuticals's Q4 earnings.

2 months ago - Benzinga

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use i...

2 months ago - Business Wire

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable an...

2 months ago - Business Wire

The European Commission has approved Xeris Pharmaceuticals Inc's (NASDAQ: XERS) Ogluo (glucagon) injection to treat severe hypoglycemia in adults, adolescents, and children aged two years and over with ...

3 months ago - Benzinga

CHICAGO & DUBLIN--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and com...

3 months ago - Business Wire

Xeris Pharmaceuticals (XERS) has moved higher as of late, but there could definitely be trouble on the horizon for this company

3 months ago - Zacks Investment Research

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable an...

3 months ago - Business Wire

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-u...

4 months ago - Business Wire

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable an...

4 months ago - Business Wire

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercializ...

4 months ago - Business Wire

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercializ...

5 months ago - Business Wire

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable an...

5 months ago - Business Wire

Last year, I was neutral about the Xeris Pharmaceuticals story; but a lot of positives have happened this year. There's a marketed product, a steadily rising revenue stream, a platform with potential, a...

5 months ago - Seeking Alpha

Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 35.19% and 111.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Shares of Xeris Pharmaceuticals (NASDAQ:XERS) moved higher by 4.6% in pre-market trading after the company reported Q3 results.

6 months ago - Benzinga

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercializ...

6 months ago - Business Wire

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use i...

6 months ago - Business Wire

Xeris Pharmaceuticals (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable an...

6 months ago - Business Wire

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable an...

8 months ago - Business Wire

Xeris has rallied substantially off its recent lows as Gvoke sales numbers have been promising.

8 months ago - Seeking Alpha

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (...

8 months ago - Business Wire

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares more than 5% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 11.27% and -11.18%, respectively, for the quarter ended June 2020.

9 months ago - Zacks Investment Research

Shares of Xeris Pharmaceuticals (NASDAQ:XERS) rose 3% in pre-market trading after the company reported Q2 results.

9 months ago - Benzinga

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (...

9 months ago - Business Wire

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use i...

9 months ago - Business Wire

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable an...

9 months ago - Business Wire

Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

9 months ago - Zacks Investment Research

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable an...

9 months ago - Business Wire

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercializ...

10 months ago - Business Wire

Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

About XERS

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglyce... [Read more...]

Industry
Biotechnology
IPO Date
Jun 21, 2018
CEO
paul Edick
Employees
180
Stock Exchange
NASDAQ
Ticker Symbol
XERS
Full Company Profile

Financial Performance

In 2020, XERS's revenue was $20.44 million, an increase of 650.73% compared to the previous year's $2.72 million. Losses were -$91.14 million, -27.42% less than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for XERS stock is "Strong Buy." The 12-month stock price forecast is 11.25, which is an increase of 252.66% from the latest price.

Price Target
$11.25
(252.66% upside)
Analyst Consensus: Strong Buy